Journals / Ulusal Romatoloji Dergisi / 2020 / Cilt: 12 - Sayı: 3

Malignancy and risk factors in systemic sclerosis patients

Sistemik sklerozis hastalarında malignite ve risk faktörleri

Pages
71–75
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SSc can be seen as a paraneoplastic syndrome, especially in patients with positive anti-RNAP-III antibody, and these patients should be monitored in terms of malignancy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Compared to the general population, malignancy is more common in patients with systemic sclerosis (SSc) and is one of the leading causes of mortality.
📊
Key Findings & Data:Methods: Medical records of 141 patients who were followed up in the Department of Rheumatology at Kocaeli University Medical Faculty Hospital and who met the 2013 American College of Rheumatology/ European League Against Rheumatism SSC classification criteria were retrospectively analyzed.
💡
Conclusion & Impact:SSc can be seen as a paraneoplastic syndrome, especially in patients with positive anti-RNAP-III antibody, and these patients should be monitored in terms of malignancy
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Compared to the general population, malignancy is more common in patients with systemic sclerosis (SSc) and is one of the leading causes of mortality. The objective of this study was to assess the frequency and types of malignancies, and its association with SSc features. Methods: Medical records of 141 patients who were followed up in the Department of Rheumatology at Kocaeli University Medical Faculty Hospital and who met the 2013 American College of Rheumatology/ European League Against Rheumatism SSC classification criteria were retrospectively analyzed. Clinical, demographic, laboratory and radiological information of the patients were obtained from the patient files. Results: Of the seven cases with malignancy, two had non-small cell lung cancer, two had breast cancer, one had larynx cancer, one had endometrium cancer, and one had chondrosarcoma. Apart from malignancy, a female patient was diagnosed with monoclonal gammopathy of undetermined significance. Four of the patients diagnosed with malignancy were evaluated as limited, and three with diffuse skin involvement. Modified Rodnan skin score was significantly higher in SSc patients with malignancy than in the patients without malignancy (p=0.045). No significant difference was found in terms of disease subtype, gender, age, auto-antibody and disease duration. Conclusion: Since the risk of malignancy is increased in patients with SSc, patients should be followed carefully. Malignancy can be diagnosed before the onset of SSc, concurrently or during the follow-up. SSc can be seen as a paraneoplastic syndrome, especially in patients with positive anti-RNAP-III antibody, and these patients should be monitored in terms of malignancy

Özet

Amaç: Sistemik sklerozis (SSk) hastalarında malignite genel topluma göre daha sık görülmektedir ve mortalitenin önde gelen nedenlerinden biridir. Bu çalışmada SSk hastalarında malignite sıklığını, tiplerini ve ilişkili olduğu SSk özelliklerini tanımlamayı amaçladık. Yöntem: Kocaeli Üniversitesi Tıp Fakültesi Hastanesi Romatoloji Bilim Dalı Kliniği’nde takip edilen ve 2013 Amerikan Romatoloji Koleji/ Avrupa Romatizma ile Mücadele Kurumu SSk sınıflama kriterlerini karşılayan 141 hastanın tıbbi kayıtları retrospektif olarak incelendi. Hastaların klinik, demografik, laboratuvar ve radyolojik bilgileri hasta dosyalarından elde edildi. Bulgular: Malignite saptanan yedi olgunun ikisinde küçük hücre dışı akciğer kanseri, ikisinde meme kanseri, birinde larinks kanseri, birinde endometriyum kanseri ve birinde kondrosarkom saptandı. Malignite dışında bir kadın hastaya önemi belirsiz monoklonal gamopati tanısı konuldu. Malignite tanısı konulan hastaların dört tanesi sınırlı, üçü yaygın deri tutulumlu SSk olarak değerlendirildi. Malignite gelişen SSk hastalarında modifiye Rodnan Deri skoru gelişmeyen hastalara göre anlamlı olarak yüksek saptandı (p=0,045). Hastalık alt tipi, cinsiyet, yaş, oto-antikor ve hastalık süresi açısından anlamlı fark bulunmadı. Sonuç: SSk hastalarında malignite riski artmış olduğundan hastalar dikkatli takip edilmelidir. Malignite tanısı SSk’nın ortaya çıkışından önce, hastalıkla eş zamanlı ya da sonrasında saptanabilir. Özellikle antiRNAP-III antikoru pozitif olan hastalarda SSk’nın paraneoplastik bir sendrom olarak görülebileceği akılda tutulmalı ve malignite açısından dikkatli olunmalıdır.

🔖

Cite This Article

Yazıcı, A., KARADAĞ, D. T., IŞIK, Ö. Ö., Tekeoğlu, S., CEFLE, A., GÖNÜL, B. (2022). Malignancy and risk factors in systemic sclerosis patients. Ulusal Romatoloji Dergisi, Cilt: 12 - Sayı: 3, 71–75. https://ajindex.com/articles/643903

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Hao Y, Hudson M, Baron M, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 2017;69:1067-77
  2. Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther 2019;21:86
  3. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008;101:59-62
  4. Szekanecz E, Andras C, Sandor Z, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 2006;6:42-7
  5. Szekanecz E, Szamosi S, Gergely L, Keszthelyi P, Szekanecz Z, Szucs G. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 2008;27:1163-6
  6. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-6
  7. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24
  8. Launay D, Le Berre R, Hatron PY, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004;23:516-22
  9. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006;18:129-34
  10. Shah AA, Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011;23:530-5
  11. Moinzadeh P, Fonseca C, Hellmich M, et al. Association of antiRNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014;16:R53
  12. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010;163:800-6
  13. Saigusa R, Asano Y, Nakamura K, et al. Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol 2015;42:524-7
  14. Lazzaroni MG, Cavazzana I, Colombo E, et al. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. J Rheumatol 2017;44:639-47
  15. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008;7:352-8
  16. Szekanecz Z, Szekanecz E, Bako G